Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc. (ENSC) is a clinical-stage pharmaceutical company operating in the healthcare and biopharmaceutical sector, with a pipeline centered on proprietary abuse-deterrent formulations for opioid and stimulant medications. The company filed a Form 10-Q with the SEC on May 3, 2018, reflecting its status as a reporting entity during an early stage of its corporate development. Ensysce subsequently completed a de-SPAC business combination that brought it onto a national U.S. exchange under the ENSC ticker, where it has continued advancing its drug-delivery platform. For complete filing history, SPAC deal analytics, and real-time research data on Ensysce and hundreds of comparable transactions, sign up for full access at SpacDesk.